GB1324737A - Prostaglandins and the preparation thereof - Google Patents

Prostaglandins and the preparation thereof

Info

Publication number: GB1324737A
Authority: GB; United Kingdom
Prior art keywords: atoms; alkyl; carbon atoms; coor; optionally substituted
Prior art date: 1970-11-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

GB4701771A

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacia and Upjohn Co

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1970-11-02

Filing date

1971-10-08

Publication date

1973-07-25

1971-10-08 Application filed by Upjohn Co filed Critical Upjohn Co

1973-07-25 Publication of GB1324737A publication Critical patent/GB1324737A/en

Status Expired legal-status Critical Current

Links

150000003180 prostaglandins Chemical class 0.000 title abstract 4
229940094443 oxytocics prostaglandins Drugs 0.000 title abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 5
125000004432 carbon atom Chemical group C* 0.000 abstract 5
125000001153 fluoro group Chemical group F* 0.000 abstract 5
-1 2-tetra-hydropyranyl Chemical group 0.000 abstract 4
125000002947 alkylene group Chemical group 0.000 abstract 3
229910052799 carbon Inorganic materials 0.000 abstract 3
125000001424 substituent group Chemical group 0.000 abstract 3
229940088710 antibiotic agent Drugs 0.000 abstract 2
125000001309 chloro group Chemical group Cl* 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
238000011200 topical administration Methods 0.000 abstract 2
SIACJRVYIPXFKS-UHFFFAOYSA-N (4-sulfamoylphenyl)methylazanium;chloride Chemical compound Cl.NCC1=CC=C(S(N)(=O)=O)C=C1 SIACJRVYIPXFKS-UHFFFAOYSA-N 0.000 abstract 1
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 abstract 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
108010001478 Bacitracin Proteins 0.000 abstract 1
101100005986 Caenorhabditis elegans cth-2 gene Proteins 0.000 abstract 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract 1
229930182566 Gentamicin Natural products 0.000 abstract 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 abstract 1
229930193140 Neomycin Natural products 0.000 abstract 1
239000004100 Oxytetracycline Substances 0.000 abstract 1
108010040201 Polymyxins Proteins 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
239000003470 adrenal cortex hormone Substances 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
229960003071 bacitracin Drugs 0.000 abstract 1
229930184125 bacitracin Natural products 0.000 abstract 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 abstract 1
125000001246 bromo group Chemical group Br* 0.000 abstract 1
229910052801 chlorine Inorganic materials 0.000 abstract 1
239000000460 chlorine Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
229910052731 fluorine Inorganic materials 0.000 abstract 1
229960000618 fluprednisolone Drugs 0.000 abstract 1
229950008849 furazolium chloride Drugs 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
FMPJXUZSXKJUQI-UHFFFAOYSA-N hydron;3-(5-nitrofuran-2-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;chloride Chemical compound Cl.O1C([N+](=O)[O-])=CC=C1C1=CSC2=NCCN12 FMPJXUZSXKJUQI-UHFFFAOYSA-N 0.000 abstract 1
LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 abstract 1
229960004584 methylprednisolone Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229960004927 neomycin Drugs 0.000 abstract 1
IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 abstract 1
229960001907 nitrofurazone Drugs 0.000 abstract 1
229960000625 oxytetracycline Drugs 0.000 abstract 1
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 abstract 1
235000019366 oxytetracycline Nutrition 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229960000268 spectinomycin Drugs 0.000 abstract 1
UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 abstract 1
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 abstract 1
229960004306 sulfadiazine Drugs 0.000 abstract 1
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
- C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
- C07C35/27—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system containing six carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

GB4701771A 1970-11-02 1971-10-08 Prostaglandins and the preparation thereof Expired GB1324737A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8630370A	1970-11-02	1970-11-02
US16744671A	1971-07-29	1971-07-29

Publications (1)

Publication Number	Publication Date
GB1324737A true GB1324737A (en)	1973-07-25

Family

ID=26774597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GB4701771A Expired GB1324737A (en)	1970-11-02	1971-10-08	Prostaglandins and the preparation thereof

Country Status (6)

Country	Link
BE (1)	BE774709A (de)
DE (1)	DE2154309C3 (de)
FR (1)	FR2112390B1 (de)
GB (1)	GB1324737A (de)
HK (1)	HK57378A (de)
NL (1)	NL174142C (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5223537A (en) *	1991-07-23	1993-06-29	Kabi Pharmacia Ab	Method and composition for treatment of gastric and duodenal disorders
US5296504A (en) *	1988-09-06	1994-03-22	Kabi Pharmacia	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) *	1988-09-06	1994-06-14	Kabi Pharmacia Ab	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5422368A (en) *	1988-09-06	1995-06-06	Kabi Pharmacia Ab	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en)	1990-04-10	2001-02-13	Pharmacia & Upjohn Aktiebolag	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6420422B1 (en)	1987-09-18	2002-07-16	Sucampo Pharmaceuticals, Inc.	Ocular hypotensive agents
US8722739B2 (en)	2008-10-29	2014-05-13	Novaer Holdings, Inc.	Amino acid salts of prostaglandins
US8906962B2 (en)	2000-03-31	2014-12-09	Duke University	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9346837B2 (en)	2000-03-31	2016-05-24	Duke University	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4011262A (en) *	1972-07-13	1977-03-08	Pfizer Inc.	13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
US3974213A (en) *	1972-07-13	1976-08-10	Pfizer Inc.	13,14-Dihydro-15-substituted-ω-pentanorprostaglandins
NO143741C (no) *	1972-07-13	1981-04-08	Pfizer	Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandinforbindelser av e- og f-serien
US3971826A (en) *	1972-07-13	1976-07-27	Pfizer Inc.	15-Substituted-ω-pentanorprostaglandins
DD118856A5 (de) *	1972-11-08	1976-03-20
US3968144A (en) *	1973-05-21	1976-07-06	The Upjohn Company	5-Oxa-11-deoxy phenyl- and phenoxy-substituted prostalandin E1 analogs
US3966795A (en) *	1973-05-21	1976-06-29	The Upjohn Company	5-Oxa-11-deoxyphenyl- and phenoxy-substituted prostaglandin F1.sub.α analogs
US4005115A (en) *	1974-01-07	1977-01-25	The Upjohn Company	Phenyl-substituted prostaglandin-A type analogs
US4001286A (en) *	1974-01-07	1977-01-04	The Upjohn Company	Phenyl-substituted prostaglandin-β-type anologs
US4328355A (en) *	1976-12-27	1982-05-04	G. D. Searle & Co.	Prostaglandin derivatives having aryl, hydroxyl, and alkynyl functions in one side chain

1971
- 1971-10-08 GB GB4701771A patent/GB1324737A/en not_active Expired
- 1971-10-29 FR FR7139126A patent/FR2112390B1/fr not_active Expired
- 1971-10-29 BE BE774709A patent/BE774709A/xx not_active IP Right Cessation
- 1971-11-02 NL NL7115049A patent/NL174142C/xx active
- 1971-11-02 DE DE19712154309 patent/DE2154309C3/de not_active Expired
1978
- 1978-09-28 HK HK57378A patent/HK57378A/xx unknown

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6420422B1 (en)	1987-09-18	2002-07-16	Sucampo Pharmaceuticals, Inc.	Ocular hypotensive agents
US5578618A (en) *	1988-09-06	1996-11-26	Pharmacia Aktiebolag	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) *	1988-09-06	1994-06-14	Kabi Pharmacia Ab	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5422369A (en) *	1988-09-06	1995-06-06	Kabi Pharmacia Ab	Prostaglanddin derivatives for the treatment of glaucoma or ocular hypertension
US5422368A (en) *	1988-09-06	1995-06-06	Kabi Pharmacia Ab	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US7163959B2 (en)	1988-09-06	2007-01-16	Pharmacia Aktiebolag	Prostagladin derivatives for the treatment of glaucoma or ocular hypertension
US6429226B1 (en)	1988-09-06	2002-08-06	Pharmacia Aktiebolag	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5627208A (en) *	1988-09-06	1997-05-06	Pharmacia Aktiebolag	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5849791A (en) *	1988-09-06	1998-12-15	Pharmacia Aktiebolag	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6030999A (en) *	1988-09-06	2000-02-29	Pharmacia & Upjohn Aktiebolag	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6417230B2 (en)	1988-09-06	2002-07-09	Pharmacia Aktiebolag	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) *	1988-09-06	1994-03-22	Kabi Pharmacia	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en)	1990-04-10	2001-02-13	Pharmacia & Upjohn Aktiebolag	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5510382A (en) *	1991-07-23	1996-04-23	Pharmacia Ab	Method for composition for treatment of gastric and duodenal disorders
US5223537A (en) *	1991-07-23	1993-06-29	Kabi Pharmacia Ab	Method and composition for treatment of gastric and duodenal disorders
US8906962B2 (en)	2000-03-31	2014-12-09	Duke University	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9346837B2 (en)	2000-03-31	2016-05-24	Duke University	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US9579270B2 (en)	2000-03-31	2017-02-28	Duke University	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9675539B2 (en)	2000-03-31	2017-06-13	Duke University	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US8722739B2 (en)	2008-10-29	2014-05-13	Novaer Holdings, Inc.	Amino acid salts of prostaglandins

Also Published As

Publication number	Publication date
DE2154309A1 (de)	1972-05-04
FR2112390B1 (de)	1975-08-01
DE2154309C3 (de)	1981-06-19
NL174142C (nl)	1984-05-01
BE774709A (fr)	1972-05-02
NL7115049A (de)	1972-05-04
DE2154309B2 (de)	1980-11-06
HK57378A (en)	1978-10-06
FR2112390A1 (de)	1972-06-16

Publication	Publication Date	Title
GB1324737A (en)	1973-07-25	Prostaglandins and the preparation thereof
GB1505305A (en)	1978-03-30	Benzcycloamide derivatives
GB1294763A (en)	1972-11-01	3-oxo-2,3-dihydro-1,4-benzoxazine derivatives
GB1285400A (en)	1972-08-16	Esters of substituted anthranilic acid
GB1439724A (en)	1976-06-16	Berbine derivatives and pharmaceutical compositions containing them
ES537542A0 (es)	1987-06-16	Procedimiento para la obtencion de derivados de ciclohexano.
GB1506817A (en)	1978-04-12	Prostaglandins
IE42784L (en)	1976-09-08	Histidine derivatives
AU576530B2 (en)	1988-09-01	1,3-dioxan-4-yl alkenoic acids
GB1293507A (en)	1972-10-18	Derivatives of 3-carbamoyl-2-oxazolidinone, and their process of preparation
GB1361863A (en)	1974-07-30	Piperazine derivatives their preparation and pharmaceutical compositions containing them
GB1424432A (en)	1976-02-11	Pharmaceutical compositions
GB1405767A (en)	1975-09-10	Method formulation and pharmaceutical composition for reducing plasma lipid levels
GB1461667A (en)	1977-01-19	Amphetamine derivatives
GB1492622A (en)	1977-11-23	Aralkyl esters of amino alkanoic acids
GB1448758A (en)	1976-09-08	Thiazole derivatives
GB1392991A (en)	1975-05-07	Prostaglandin derivatives and the preparation thereof
ES428673A1 (es)	1976-09-01	Procedimiento para la obtencion de derivados de nitrobenzo-fenona sustituidos.
GB1492439A (en)	1977-11-16	Prostaglandins
GB1381833A (en)	1975-01-29	Amino acid derivatives
GB1454726A (en)	1976-11-03	Penicillins and cephalosporins
GB1493521A (en)	1977-11-30	8-(beta-aminoethyl)ergolines-i and a method of preparing same
GB1322640A (en)	1973-07-11	Selected 5-substituted-5-phenylalkyl barbituric acids analgetic compositions and method based thereon
GB1436831A (en)	1976-05-26	Prostaglandins and the preparation thereof
ES344827A1 (es)	1968-11-01	Un procedimiento para la preparacion de 9beta, 10alfa-este-roides.

Legal Events

Date	Code	Title	Description
1973-12-05	PS	Patent sealed
1986-06-11	PCNP	Patent ceased through non-payment of renewal fee